Evidence map›Paper›PMID 40877952›Full record

SynthesisOrphanet journal of rare diseases2025

Diagnosis and management of cystinosis: systematic review for a clinical practice guideline.

Dominic Ledinger, Barbara Nussbaumer-Streit, Brigitte Piso, Andreea Dobrescu, Arianna Gadinger, Irma Klerings, Katharina Hohenfellner, Isolde Sommer

Abstract readSystematic ReviewReview
In one paragraph

Synthesis in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dominic LedingerDepartment for Evidence-based Medicine and Evaluation, University for Continuing Education Krems, Krems, Austria. dominic.ledinger@donau-uni.ac.at.ORCID http://orcid.org/0000-0002-2031-5398
Barbara Nussbaumer-StreitDepartment for Evidence-based Medicine and Evaluation, University for Continuing Education Krems, Krems, Austria.
Brigitte PisoDepartment for Evidence-based Medicine and Evaluation, University for Continuing Education Krems, Krems, Austria.
Andreea DobrescuDepartment for Evidence-based Medicine and Evaluation, University for Continuing Education Krems, Krems, Austria.
Arianna GadingerDepartment for Evidence-based Medicine and Evaluation, University for Continuing Education Krems, Krems, Austria.
Irma KleringsDepartment for Evidence-based Medicine and Evaluation, University for Continuing Education Krems, Krems, Austria.
Katharina HohenfellnerDepartment of Pediatrics, Pediatric Nephrology, RoMed Kliniken, Rosenheim, Germany.
Isolde SommerDepartment for Evidence-based Medicine and Evaluation, University for Continuing Education Krems, Krems, Austria.

Funding

Gemeinsame Bundesausschuss 01VSF22003
6 · The paper itself

Abstract

backgroundCystinosis is a rare genetic disorder, with the majority of patients suffering from infantile nephropathic cystinosis, the most severe form. If left untreated, cystinosis causes serious morbidity, initially through progressive kidney and eye disease, followed by systemic and multiorgan involvement, ultimately leading to premature death. In this systematic review, we summarize the evidence for cystinosis to support the development of an evidence-based clinical practice guideline (SELECT - S3 guideline for cystinosis).

methodsWe searched MEDLINE, Embase, CENTRAL, CINAHL, and other databases for relevant studies published from 1980 onward. We screened literature dually and independently for eligibility. Primary researchers extracted data, rated the risk of bias of included studies, and rated the certainty of the evidence (CoE). Secondary researchers reviewed for completeness and accuracy. We applied a staggered approach, prioritizing available controlled studies and synthesizing results narratively.

resultsWe considered 56 studies in our synthesis and assessed findings relevant to 17 of 31 key questions. We identified evidence for 62 of 213 outcomes. Fifty-two outcomes had very low CoE, three low, four moderate, and three high. The moderate and high CoE findings came from indirect comparisons (other chronic multi-organ diseases). There was low evidence that delayed-release cysteamine therapy makes little to no difference on cystine levels compared to immediate-release cysteamine therapy; however, delayed-release cysteamine was associated with a slight increase in adverse events. Starting systemic cysteamine treatment early likely improves renal function compared to a later start. Most included studies lacked a control group, had a high risk of bias, and had a small sample size.

conclusionEvidence informing the diagnosis and management of cystinosis is limited, with most findings rated as very low certainty. Few direct comparisons involving only individuals with cystinosis yielded low certainty findings, while moderate to high certainty evidence was found only in indirect comparisons. These findings underscore a critical challenge in managing cystinosis: the balancing act of clinical decision-making in the context of lacking evidence. Nonetheless, this systematic review synthesized the best available data for a clinical practice guideline and highlighted specific areas where future research could strengthen the evidence base.

Indexed as

CystinosisHumansPractice Guidelines as TopicCystinosisGenetic autosomal recessive disorderGuideline developmentMultisystemic diseaseNephropathic cystinosisOrphan diseaseSystematic review

Identifiers

PMID40877952
PMCPMC12395644

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.